Related Experiment Video
Updated: Apr 5, 2026

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3
Published on: August 17, 2011
Inhibition of 2-methoxyestradiol glucuronidation by probenecid
Yuli Qian1, Ahmad Sherbini1, Bahar Matin1
1Graduate Program in Pharmacology and Drug Development, Sackler School of Graduate Biomedical Science, Tufts University School of Medicine, Boston, MA, USA.
Objectives:
2-Methoxyestradiol (2ME2), a metabolite of estradiol, has antitumour activity in vitro. However, potential clinical applicability has been limited by low oral bioavailability. Probenecid was evaluated in vitro as an inhibitor of 2ME2 glucuronidation for purposes of enhancing 2ME2 oral bioavailability.
Methods:
Human liver microsomes were used to determine kinetic parameters for transformation of 2ME2 to its glucuronide metabolites (M1, M2) and inhibition of the reactions by probenecid.
Key Findings:
M1 and M2 formation from 2ME2 proceeded with features of substrate inhibition. Probenecid inhibited metabolite formation, with mean inhibition constant (Ki ) values of 0.9 and 2.6 mM, respectively. Inhibition was reversible, with mixed competitive-non-competitive characteristics.
Conclusion:
The Ki values for probenecid inhibition of 2ME2 glucuronide formation, when compared to maximum probenecid plasma concentrations anticipated clinically, indicate that probenecid co-administration has the potential to augment systemic plasma levels of 2ME2 after oral dosage in humans.
More Related Videos
Related Concept Videos
Drug Metabolism: Phase II Reactions
Phase II Reactions: Glucuronidation
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drug Elimination by Renal Route: Tubular Secretion
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics: Drug–Drug Interactions

